Drugs / solamargine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02559934 | Nov 2015 → Jan 2019 | actinic keratosis | G&E Herbal Biotechnology Co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT02029066 | Nov 2013 → Feb 2014 | actinic keratosis | G&E Herbal Biotechnology Co., LTD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | solamargine | “0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)” NCT02559934 ↗1“This study is designed to evaluate the pharmacokinetics of solamargine of SR-T100 gel.” NCT02029066 ↗ |
| Known as | SR-T100 | “This study is designed to evaluate the pharmacokinetics of solamargine of SR-T100 gel.” NCT02029066 ↗ |
| Modality | Small molecule | — CHEMBL443114 ↗ |
| Route | Topical | “2g of SR-T100 will topical apply on 100 cm\^2 once for 24 hours.” NCT02029066 ↗ |